RNAC Q4 2024 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$759,000-109.2% YoY

Gross Profit

-$759,000100.0% margin

Operating Income

-$27M3521.9% margin

Net Income

-$10M1350.9% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

-296.1%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$435M

Total Liabilities

$442M

Stockholders' Equity

-$7M

Cash & Equivalents

$213M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$759,000	$8M	-109.2%
Gross Profit	-$759,000	$8M	-109.2%
Operating Income	-$27M	-$36M	+26.4%
Net Income	-$10M	-$178M	+94.2%